| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/19/2006 | US20060234905 Method of stimulating growth and resistance to diseases of aquatic organisms |
| 10/19/2006 | US20060234373 Treatment for diabetes |
| 10/19/2006 | US20060234367 Yeast cells; ribonuclease barnase marker gene; libraries; drug resistance |
| 10/19/2006 | US20060234352 Homogeneity and secretion of recombinant proteins in mammalian systems |
| 10/19/2006 | US20060234351 Yeast protein expression secretion system |
| 10/19/2006 | US20060234350 Endogenous and non-endogenous versions of human G protein-coupled receptors |
| 10/19/2006 | US20060234349 Fungal cell wall synthesis gene |
| 10/19/2006 | US20060234344 Protein kinases |
| 10/19/2006 | US20060234343 deletion of residues in the CR2 domain of the EGFR ectodomain gives rise to a truncated ectodomain with enhanced affinity for epidermal growth factors such as (EGF) and/or transforming growth factor-I (TGF- alpha ); psoriasis and tumor states |
| 10/19/2006 | US20060234342 Human DNA topoisomerase I alpha |
| 10/19/2006 | US20060234306 Assay method |
| 10/19/2006 | US20060234297 Screening method |
| 10/19/2006 | US20060234292 Methods of diagnosing and treating diabetes and insulin resistance |
| 10/19/2006 | US20060234289 Sp110, a polypeptide component of the nuclear body |
| 10/19/2006 | US20060234286 Human paris-1 antigen and nucleic acids: diagnostic and therapeutic uses |
| 10/19/2006 | US20060234285 For treating or preventing inflammatory diseases, autoimmune diseases, graft versus host disease (GVHD), allergis, asthma, and/or hepatitis; drug screening |
| 10/19/2006 | US20060234283 reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered; antifungal agents; inhibiting expression of cell wall glycoproteins and preventing pathogens from showing pathogenicity |
| 10/19/2006 | US20060234271 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 10/19/2006 | US20060234255 Novel proteins and nucleic acids encoding same |
| 10/19/2006 | US20060234240 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 1f receptor (5-ht1f) |
| 10/19/2006 | US20060234239 An oligonucleotide targeted to (hybridizing with) a nucleic acid molecule encoding human insulin like growth factor I receptor; treatment of proliferative and inflammatory skin disorders and cancer |
| 10/19/2006 | US20060234233 Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes |
| 10/19/2006 | US20060234218 P450 proteins |
| 10/19/2006 | US20060234213 Synthetic peptides useful in biological essays for detecting infections caused by group O HIV-1 viruses |
| 10/19/2006 | US20060234208 Novel mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism |
| 10/19/2006 | US20060234205 In vitro test system for predicting patient tolerability of therapeutic agents |
| 10/19/2006 | US20060233884 Sexual hygienic composition |
| 10/19/2006 | US20060233855 Administering a synthetic polymer ( biodegradable, nonbiodegradable polymers e.g. polylactic acid, PTFE) attached to denatured, uncleaved fibrinogen being subject to proteolytic and hydrolytic degradation in a patient in need of bone tissue, thereby regenerating the bone or cartilage tissues |
| 10/19/2006 | US20060233854 Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same |
| 10/19/2006 | US20060233841 Implantable gel compositions and method of manufacture |
| 10/19/2006 | US20060233833 Novel uses of parapoxvirus preparations |
| 10/19/2006 | US20060233827 85kDa neisserial antigen |
| 10/19/2006 | US20060233822 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof |
| 10/19/2006 | US20060233819 Inhibition of T cell activation by butyrophilin 4 or B7-L1 |
| 10/19/2006 | US20060233818 Organic compounds |
| 10/19/2006 | US20060233814 Elimination of heterogeneous or mixed cell population in tumors |
| 10/19/2006 | US20060233813 Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith |
| 10/19/2006 | US20060233811 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 10/19/2006 | US20060233810 Methods and compositions for treating or preventing cancer |
| 10/19/2006 | US20060233807 Novel therapies and methods of screening for therapeutic compounds |
| 10/19/2006 | US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo |
| 10/19/2006 | US20060233805 Antigen uptake receptor for candida albicans on dendritic cells |
| 10/19/2006 | US20060233804 IGF antagonist peptides |
| 10/19/2006 | US20060233803 treating an inflammatory disorder characterized by elevated expression of the polypeptide of SEQ ID NO: 32 in human, comprising administering an immunoadhesin comprising an extracellular domain sequence of the polypeptide; rheumatoid arthritis, pneumonia, chronic asthma, chronic hepatitis, osteoarthritis |
| 10/19/2006 | US20060233802 Tumour necrosis factor binding ligands |
| 10/19/2006 | US20060233799 Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases |
| 10/19/2006 | US20060233796 Method of modulating memory effector T-cells and compositions |
| 10/19/2006 | US20060233792 novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents |
| 10/19/2006 | US20060233786 Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
| 10/19/2006 | US20060233785 Immunointeractive molecules and uses thereof |
| 10/19/2006 | US20060233784 ADAMTS13 genes and proteins and variants, and uses thereof |
| 10/19/2006 | US20060233783 Topical composition in the form of a gel for treating skin burns |
| 10/19/2006 | US20060233782 Polypeptide; a deletion mutant of chondroitinase ABC Type I truncated by a deletion; retains its proteoglycan degrading activity; neurological functional recovery after central nervous system injury or disease |
| 10/19/2006 | US20060233781 Antimicrobial composition for local use on mucosal membranes and skin |
| 10/19/2006 | US20060233780 Method for treating oncological diseases |
| 10/19/2006 | US20060233779 Ring finger family proteins and uses related thereto |
| 10/19/2006 | US20060233778 Stability for injection solutions |
| 10/19/2006 | US20060233777 Use of bacteriocin for the amelioration of digestive functionality |
| 10/19/2006 | US20060233776 C1-inh as a drug for treating viruses pathogenic to humans |
| 10/19/2006 | US20060233771 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| 10/19/2006 | US20060233769 Established cell line of microglia |
| 10/19/2006 | US20060233755 A virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient; gene therapy for the prevention and treatment of deafness |
| 10/19/2006 | US20060233751 Population of natural cells, 50% are autoantigen-specific regulatory T cells |
| 10/19/2006 | US20060233750 Materials and method of modulating the immune response |
| 10/19/2006 | US20060233749 Interleukin-19 |
| 10/19/2006 | US20060233748 Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease |
| 10/19/2006 | US20060233747 Polymer-modified synthetic proteins |
| 10/19/2006 | US20060233746 N-terminally chemically modified protein compositions and methods |
| 10/19/2006 | US20060233745 Enclosures housing cell-coated supports for treating tumors |
| 10/19/2006 | US20060233744 Orthogonal tRNA synthetase that aminoacylates with reduced efficiency; lower km and recognizes selector codon in mRNA |
| 10/19/2006 | US20060233743 Compositions and methods of therapy |
| 10/19/2006 | US20060233742 cyclic peptides blocking of the Casein Kinase II (CKII) phosphorylation domain; HPV-16 cervical carcinoma cells; peptides increase the sensitivity of the cells to the cytostatic effect of IFN |
| 10/19/2006 | US20060233740 Conjugates of an hGH moiety and a polymer |
| 10/19/2006 | US20060233715 Compositions for nasal administration of drug |
| 10/19/2006 | US20060233708 Peptide antagonists of TGF-beta family members and therapeutic uses thereof |
| 10/19/2006 | US20060233706 Marked peptides having affinity for a phospholipid and uses |
| 10/19/2006 | US20060233704 Prochelator for the preparation of radiometal labeled molecules having improved biological properties |
| 10/19/2006 | DE202006001133U1 Multifunctional active agent mixture, useful as auxiliary material in virus vaccine or vaccine to treat cancer, comprises fraction of specific peptide in polypetide chain and fraction with essential and non-essential amino acids |
| 10/19/2006 | DE19720437B4 Mutanase enthaltende orale Zusammensetzungen Mutanase containing oral compositions |
| 10/19/2006 | DE102005017799A1 Use of heparin- or heparin derivative to treat illness associated with neurite plasticity or -growth defects, modulates interaction between Nogo receptor and ligands |
| 10/19/2006 | DE102005016230A1 Vorrichtung zur Trockenvernebelung Apparatus for dry nebulization |
| 10/19/2006 | CA2605253A1 Selective modulation of tumour necrosis factor receptors in therapy |
| 10/19/2006 | CA2604952A1 Dietary supplement formulations for improved delivery of coenzyme q10 and methods of administration |
| 10/19/2006 | CA2604885A1 Cacna1e in cancer diagnosis, detection and treatment |
| 10/19/2006 | CA2604536A1 Conjugate comprising p21 protein for the treatment of cancer |
| 10/19/2006 | CA2604327A1 Pharmaceutical aerosol composition |
| 10/19/2006 | CA2604198A1 Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab) |
| 10/19/2006 | CA2604135A1 Pop2 nfkb-inhibiting polypeptides, nucleic acids and methods of use |
| 10/19/2006 | CA2604007A1 Use of fril proteins for reducing the production of pro-inflammatory cytokines |
| 10/19/2006 | CA2603850A1 Polymyxin b analogs for lps detoxification |
| 10/19/2006 | CA2603779A1 Chimeric proteins comprising yersinia yop, their preparation and pharmaceutical compositions containing them |
| 10/19/2006 | CA2597789A1 Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
| 10/19/2006 | CA2587848A1 Antiinfective lipopeptides |
| 10/18/2006 | EP1712628A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 10/18/2006 | EP1712620A1 Peptide originating in epidermal growth factor receptor (egfr) |
| 10/18/2006 | EP1712566A1 Inflammatory cytokine inhibitor |
| 10/18/2006 | EP1712560A1 Hypoallergenic proteins derived from the major allergen of parietaria judaica |
| 10/18/2006 | EP1712559A1 Polymyxin B analogs for LPS detoxification |
| 10/18/2006 | EP1712243A1 Gene therapy for tumor using minus-strand rna viral vectors encoding immunostimulatory cytokines |
| 10/18/2006 | EP1712239A2 Interleukin-1 inhibitors in the treatment of diseases |